Brian Angus
BSc, MBChB, DTM&H, FRCP, MD, FFTM
Professor of Practice, Medical Education and Reader in Infectious Diseases
- Assistant Director of Graduate Studies
- Reader in Infectious Diseases
- Associate Professor
- Clinical Tutor in Medicine
Professor Brian Angus is the Director of the Oxford Centre for Clinical Tropical Medicine and Global Health. He joined the Nuffield Department of Clinical Medicine in 1993 and originally worked in Thailand and Ghana studying pharmacokinetics in severe malaria and melioidosis. His research focus is now on clinical trials and vaccine development in COVID, malaria, influenza, HIV, Chronic Fatigue Syndrome, and enteric fever. He is Clinical Tutor in Medicine and Associate Professor and Reader in Infectious Diseases at the University of Oxford. He holds an honorary Senior Clinical Scientist tltle at the MRC CTU.
Key publications
-
T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.
Journal article
Chen J-L. et al, (2025), Nat Commun, 16
Recent publications
-
T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.
Journal article
Chen J-L. et al, (2025), Nat Commun, 16
-
The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis.
Journal article
Woolley SD. et al, (2025), J Antimicrob Chemother, 80, 1455 - 1457
-
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Journal article
Venkatraman N. et al, (2025), Lancet Microbe, 6
-
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Journal article
Venkatraman N. et al, (2025), Lancet Microbe, 6
-
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.
Journal article
Singh K. et al, (2024), J Infect Dis, 230, 624 - 634